Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 18/20 | 0.77 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456785 | 0.88 | PDPK1 (0.63) | PDPK1PIK3CAPIK3CGALK | |
| SCHEMBL1456341 | 0.87 | PDPK1 (0.60) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL1604696 | 0.87 | PDPK1 (1.00) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL1456750 | 0.86 | PDPK1 (0.79) | PDPK1PIK3CAPIK3CGALK | |
| SCHEMBL1456545 | 0.86 | PDPK1 (0.66) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL2427679 | 0.85 | PDPK1 (0.79) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL1456803 | 0.85 | PDPK1 (0.80) | PDPK1PIK3CA | |
| SCHEMBL27806455 | 0.84 | PDPK1 (0.61) | PDPK1PIK3CAPIK3CGALK | |
| SCHEMBL1456952 | 0.83 | PDPK1 (0.75) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL1456730 | 0.82 | PDPK1 (0.54) | PDPK1PIK3CAPIK3CGALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420820-B2 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8420820-B2 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2011-09-08 | — | — | US | disclosed |
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2011-09-08 | — | — | US | disclosed |
| EP-2291375-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| WO-2010000364-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MKI67, CCNT1, CCNI | PDPK1 429/4885PIK3CA 2075/4885PIK3CG 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.